#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

The role of allogeneic haematopoietic stem cell transplantation in the treatment of acquired aplastic anaemia in children – experience in the Czech Republic from 1991-2007


Authors: Pindurová E.ihash2ihash4ihash6ihash8ihash10ihash12ihash14ihash16ihash18ihash20ihash22 Pro Pracovní Skupinu Dětské Hematologie (psdh) 1 1 1 1 1 1 1 1 1 2 3 1
Authors‘ workplace: Klinika dětské hematologie a onkologie, 2. lékařská fakulta a FN v Motole, Praha, Ústav hematologie a krevní transfuze, Praha, Radioterapeuticko-onkologické oddělení FN Motol, Praha 1
Published in: Transfuze Hematol. dnes,17, 2011, No. 3, p. 122-129.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

Allogeneic haematopoietic stem cell transplantation has a defined role in the treatment scheme of acquired aplastic anaemia in children. This article summarises the development and current status of such treatment in paediatric patients in the Czech Republic, covering a period of 17 years (1991–2007). During this period, a total of 38 children underwent transplantation, of which 74% were transplanted using grafts from HLA matched siblings (n=28) and 26% (n=10) from alternative donors. Median follow-up was 9.8 years (3.3 – 20.3). 5 year overall survival of the entire group is 92±4.3% (CI 95%) – sibling donor group 96±3.5%, alternative donor group 80±12.6%. The principal complication and cause of morbidity and mortality is GVHD – higher in the group of recipients of alternative grafts as expected. Our experience demonstrates the benefit of allogeneic hematopoietic stem cell transplantation in children suffering from acquired aplastic anaemia. Very satisfactory results have been achieved mainly in the group of unrelated matched donors. The main trend has been to optimise conditioning regimens with the aim of reducing both early and late toxicity, also in view of possible late effects.

Key words:
acquired aplastic anaemia, immunosuppressive therapy, haematopoietic stem cell transplantation, alternative donor, conditioning


Sources

1. Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol 2007; 136: 549-564.

2. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509-2519.

3. Scheinberg P, Cooper JN, Sloand EM. Association of telomerase length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA 2010; 304: 1358-1364.

4. Hrodek O, Hyniová H, Chudomel V. Dřeňové útlumy u dětí. Čs Pediatrie 1982; 37 (10): 562-570.

5. Starý J, Sedláček P, Kobylka P, et al. Významný pokrok v léčbě získané aplastické anémie u dětí v 90. letech. Čs Pediatrie 1998; 53 (5): 260-266.

6. Kojima S, Horine K, Inaba J, et al. Long term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol 2000; 111: 321-328.

7. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003; 101: 1236-1242.

8. Armand P, Antin JH. Allogeneic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant 2007; 13: 505-516.

9. Koza V, Cetkovský P, Faber E, et al. Indikace k alogenním a autologní transplantacím krvetvorných buněk. Doporučení ČHS ČLS JEP a ČOS ČLS JEP. Transfuze Hematol dnes 2006, 4: 223-231.

10. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974; 18: 295-304.

11. Hofman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol 2004; 125: 435-454.

12. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147: 43-70.

13. Pulsipher MA, Young NS, Tolar J, et al. Optimization of therapy for severe aplastic anemia based on clinical, biologic and treatment response parameters: Conclusion of an International Working Group on Severe Aplasti Anemia convened by the Blood and Marrow Transplant Clinical Network, March 2010. Biol Blood Marrow Transplant 2011; 17: 291-299.

14. Storb R, Longton G, Anasetti C, et al. Changing trends in marrow transplantation for aplastic anemia. Bone Marrow Transplant 1992; 10: 45-52.

15. Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007; 109: 4582-4585.

16. Kahl Ch, Leisenring W, Deek HJ, et al. Cyclophosphamide and antithymocyte globulin as a conditioning regiment for allogeneic marrow transplantation in patients with aplastic anaemia: a long term follow up. Br J Haematol 2005; 130: 747-751.

17. Schrezeinmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD vith peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110:1397-1400.

18. Stalder MP, Rovó A, Halter J, et al. Aplastic anemia and concomitant autoimmune diseases. Ann Hematol 2009; 88(7): 659-656.

19. Kojima S, Inaba J, Yoshimi A, et al. Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br J Haematol 2001; 114: 706-711.

20. Kojima S, Matsuyama T, Kato S, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 2002; 100: 799-803

21. Kim SY, Lee JW, Lim J, et al. Unrelated donor Bone marrow transplantants for severe aplastic anemia with conditioning using total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant 2007; 13:863-870.

22. Deeg HJ, OęDonnell M, Tolar J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006; 108: 1485-1491.

23. Inagaki J, Nagatoshi Y, Kawano Y, et al. Bone marrow transplantation in children with severe aplastic anemia using a conditioning regiment containing 3 Gy of total body irradiation, cyclophosphamide with or without antithymocyte globulin. Pediatr Transplant 2007; 11: 180-186.

24. Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from EBMT-SAA Working party. Bone Marrow Transplant 2005; 36: 947-950.

25. Gupta V, Ball SE, Sage D, et al. Marrow tranplantants from matched unrelated donors for aplastic anaemia using alemtuzab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transplant 2005; 35: 467-471.

26. Kang HJ, Shin HY, Choi HS, et al. Fludarabine, cyclophosphamide plus thymoglobulin conditioning regiment for unrelated bone marrow transplantation in severe aplastic anaemia. Bone Marrow Transplant 2004; 34: 939-943.

27. Maury S, Balere-Appert ML, Chir Z, et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high resolution HLA matching between donor and recipient. Haematologica 2007; 92: 589-596.

28. Siegal D, Xu W, Sutherland R, et al. Graft-versus-host disease following marrow transplantation for aplastic anaemia: different impact of two GVHD prevention strategies. Bone Marrow Transplant 2008; 42: 51-56.

Labels
Haematology Internal medicine Clinical oncology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#